Introduction of Valrubicin

Valrubicin is a cancer (antineoplastic) medication. Valrubicin interferes with the growth of cancer cells and slows their growth and spread in the body. Valrubicin is used to treat bladder cancer. Valrubicin may also be used for purposes other than those listed in this medication guide

Side effects of Valrubicin

If you experience an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives) to valrubicin, seek emergency medical attention.

Other, less serious side effects may be more likely to occur. Continue taking valrubicin and talk to your doctor if you experience:

• bladder irritation (increased frequency of urination, painful urination, a very strong feeling of needing to urinate, blood in the urine);

• urinary incontinence

• urinary tract infection

• red colored urine for 24 hours following a dose; or

• nausea

Talk to your doctor immediately if you have prolonged (longer than 24 hours after a dose) red-colored urine or prolonged bladder irritation.

Other side effects have also been reported. Discuss with your doctor any side effect that occurs during treatment with valrubicin.

Warning of Using Valrubicin

Do not use valrubicin without first talking to your doctor if you have 

• a urinary tract infection;

• a perforated or otherwise damaged bladder;

• kidney disease; or

• irritable bladder disorder

The use of valrubicin may be dangerous if you have any of the conditions listed above.

Valrubicin is in the FDA pregnancy category C. Systemic exposure to valrubicin may result in harm to an unborn baby. Do not use valrubicin without first talking to your doctor if you are pregnant. Men and women being treated with valrubicin should discuss with their doctor the appropriate use of birth control during treatment with valrubicin if necessary.

Because of the potential for serious side effects in a nursing infant, breast-feeding should be avoided during treatment with valrubicin.

The safety and effectiveness of valrubicin in children has not been established.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.